A Novel Fusion of ALT-803 (Interleukin (IL)-15 Superagonist) with an Antibody Demonstrates Antigen-specific Antitumor Responses

Fc receptor-mediated phagocytosis in tissues as a potent mechanism for preventive and therapeutic HIV vaccine strategies

(2016) M Sips et al.   Mucosal Immunology

Synergistic Innate and Adaptive Immune Response to Combination Immunotherapy with Anti-Tumor Antigen Antibodies and Extended Serum Half-Life IL-2

(2015) Eric F. Zhu et al.   CANCER CELL

Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect

(2015) David J. DiLillo et al.   CELL

The IL-15-Based ALT-803 Complex Enhances Fc RIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas

(2015) M. Rosario et al.   CLINICAL CANCER RESEARCH

ImmunoPET of tissue factor expression in triple-negative breast cancer with a radiolabeled antibody Fab fragment

(2015) Sixiang Shi et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Therapeutic administration of IL-15 superagonist complex ALT-803 leads to long-term survival and durable antitumor immune response in a murine glioblastoma model

(2015) Dimitrios Mathios et al.   INTERNATIONAL JOURNAL OF CANCER

PET Imaging of Abdominal Aortic Aneurysm with 64Cu-Labeled Anti-CD105 Antibody Fab Fragment

(2015) S. Shi et al.   JOURNAL OF NUCLEAR MEDICINE

In VivoActivation of Human NK Cells by Treatment with an Interleukin-15 Superagonist Potently Inhibits AcuteIn VivoHIV-1 Infection in Humanized Mice

(2015) Kieran Seay et al.   JOURNAL OF VIROLOGY

Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial

(2015) Peter Hillmen et al.   LANCET

Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal Models

(2015) P. R. Rhode et al.   Cancer Immunology Research

NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy

(2015) Wei Wang   Frontiers in Immunology

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

(2014) Valentin Goede et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Mechanism-of-Action of a Novel Superagonist Interleukin-15: Interleukin-15 Receptor  Su/Fc Fusion Complex in Syngeneic Murine Models of Multiple Myeloma

(2013) W. Xu et al.   CANCER RESEARCH

The IL-15-based superagonist ALT-803 promotes the antigen-independent conversion of memory CD8+T cells into innate-like effector cells with antitumor activity

(2013) Hing C Wong et al.   OncoImmunology

Antibody-Dependent Cellular Cytotoxicity against Primary HIV-Infected CD4+T Cells Is Directly Associated with the Magnitude of Surface IgG Binding

(2012) Adjoa Smalls-Mantey et al.   JOURNAL OF VIROLOGY

IL-15:IL-15 receptor alpha superagonist complex: High-level co-expression in recombinant mammalian cells, purification and characterization

(2011) Kai-ping Han et al.   CYTOKINE

Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response

(2010) R. Abes et al.   BLOOD

The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive Immunity

(2010) SaeGwang Park et al.   CANCER CELL

Interleukin-15:Interleukin-15 receptor   scaffold for creation of multivalent targeted immune molecules

(2010) R. L. Wong et al.   PROTEIN ENGINEERING DESIGN & SELECTION

CD20-Targeted Therapy: The Next Generation of Antibodies

(2010) Tom van Meerten et al.   SEMINARS IN HEMATOLOGY

CD20 as a Target for Therapeutic Type I and II Monoclonal Antibodies

(2010) Stephen A. Beers et al.   SEMINARS IN HEMATOLOGY

Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab

(2009) S. P. Hilchey et al.   BLOOD

Novel Human Interleukin-15 Agonists

(2009) X. Zhu et al.   JOURNAL OF IMMUNOLOGY

Development of Novel Tetravalent Anti-CD20 Antibodies with Potent Antitumor Activity

(2008) B. Li et al.   CANCER RESEARCH